Application of extracellular vesicles derived from mesenchymal stem cells as potential therapeutic tools in autoimmune and rheumatic diseases

International Immunopharmacology, Journal Year: 2022, Volume and Issue: 106, P. 108634 - 108634

Published: Feb. 19, 2022

Language: Английский

---

The impact of interleukin-6 (IL-6) and mesenchymal stem cell-derived IL-6 on neurological conditions

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: June 24, 2024

Interleukin-6 (IL-6) is a versatile cytokine crucial for immune response modulation, inflammation regulation, and various physiological processes in the body. Its wide-ranging functions underscore its importance maintaining health. Dysregulated IL-6 closely associated with many diseases, making it key research therapeutic target. Elevated levels central nervous system worsen neuroinflammation neurodegenerative diseases by activating microglia astrocytes releasing pro-inflammatory cytokines neurotoxic molecules. Moreover, dysregulated weakens blood-brain barrier, exacerbating neuronal damage allowing peripheral cells inflammatory mediators to enter brain. Mesenchymal stem (MSCs) show promise modulating regulating levels. They effectively suppress cytokines, including IL-6, while promoting anti-inflammatory factors. This approach highlights of targeting other alleviate adverse effects on neurological disorders. review provides comprehensive overview IL-6’s involvement disorders, examining endogenous derived from MSCs. We explore mechanisms affecting function, survival, modulation system. Additionally, we discuss potential MSC-derived neuroregeneration neuroprotection. By elucidating interplay pathologies, this offers insights into novel strategies signaling pathways

Language: Английский

---

Re-establishing immune tolerance in multiple sclerosis: focusing on novel mechanisms of mesenchymal stem cell regulation of Th17/Treg balance

Journal of Translational Medicine, Journal Year: 2024, Volume and Issue: 22(1)

Published: July 15, 2024

The T-helper 17 (Th17) cell and regulatory T (Treg) axis plays a crucial role in the development of multiple sclerosis (MS), which is regarded as an immune imbalance between pro-inflammatory cytokines maintenance tolerance. Mesenchymal stem (MSC)-mediated therapies have received increasing attention MS research. In its animal model experimental autoimmune encephalomyelitis, MSC injection was shown to alter differentiation CD4

Language: Английский

---

Human umbilical cord derived mesenchymal stem cells overexpressing HO‐1 attenuate neural injury and enhance functional recovery by inhibiting inflammation in stroke mice

CNS Neuroscience & Therapeutics, Journal Year: 2023, Volume and Issue: 30(2)

Published: Aug. 17, 2023

Abstract Aims The current evidence demonstrates that mesenchymal stem cells (MSCs) hold therapeutic potential for ischemic stroke. However, it remains unclear how changes in the secretion of MSC cytokines following overexpression heme oxygenase‐1 (HO‐1) impact excessive inflammatory activation a mouse stroke model. This study investigated this aspect and provided further insights. Methods middle cerebral artery occlusion (MCAO) model was established, subsequent injections MSC, HO‐1 , or PBS solutions equal volume were administered via mice's tail vein. Histopathological analysis conducted on Days 3 28 post‐MCAO to observe morphological brain slices. mRNA expression levels various factors, including IL‐1β, IL‐6, IL‐17, TNF‐α, IL‐1Ra, IL‐4, IL‐10, TGF‐β, quantified. effects treatment neurons, microglia, astrocytes observed using immunofluorescence after transplantation. polarization direction macrophages/microglia also detected flow cytometry. Results results showed anti‐inflammatory factors group increased while pro‐inflammatory decreased. Small animal fluorescence studies assays homing function MSCs unaffected, leading substantial accumulation region within 24 h. Neurons less damaged, proliferation microglia reduced, M2 type Furthermore, transplantation mortality mice decreased, motor improved significantly. Conclusion findings indicate overexpressing exhibited significant against hyper‐inflammatory injury mice, ultimately promoting recovery

Language: Английский

---

Concurrently bioprinted scaffolds with autologous bone and allogeneic BMSCs promote bone regeneration through native BMSC recruitment

Bio-Design and Manufacturing, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 10, 2025

Language: Английский

---

Idiopathic pulmonary fibrosis microenvironment: Novel mechanisms and research directions

International Immunopharmacology, Journal Year: 2025, Volume and Issue: 155, P. 114653 - 114653

Published: April 14, 2025

Language: Английский

---

Hematopoiesis during Ontogenesis, Adult Life, and Aging

International Journal of Molecular Sciences, Journal Year: 2021, Volume and Issue: 22(17), P. 9231 - 9231

Published: Aug. 26, 2021

In the bone marrow of vertebrates, two types stem cells coexist—hematopoietic (HSCs) and mesenchymal (MSCs). Hematopoiesis only occurs when these cell their descendants interact. The HSCs supply body with all mature blood cells, while MSCs give rise to stromal that form a niche for regulate process hematopoiesis. studies hematopoiesis were initially based on morphological observations, later extended by use physiological methods, subsequently augmented massive application sophisticated molecular techniques. combination methods produced wealth new data organization functional features in ontogenesis mammals humans. This review summarizes current views mice humans, discusses development elements embryo, describes how hematopoietic system works adult organism it changes during aging.

Language: Английский

---

Cell therapy with placenta-derived mesenchymal stem cells for secondary progressive multiple sclerosis patients in a phase 1 clinical trial

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: May 8, 2025

Language: Английский

---

Universal or Personalized Mesenchymal Stem Cell Therapies: Impact of Age, Sex, and Biological Source

Cells, Journal Year: 2022, Volume and Issue: 11(13), P. 2077 - 2077

Published: June 30, 2022

Mesenchymal stem/stromal cells (MSCs) hold great promise for the treatment of autoimmune conditions given their immunomodulatory properties. Based on low immunogenicity MSCs, it is tempting to consider expansion MSCs from a “universal donor” in culture prior allogeneic applications immediate care. This raises critical question criteria we should use select best donor”. It also imperative compare “universal” approach with “personalized” one clinical value. In addition call MHC-matching, recent studies suggest that factors including age, sex, and biological sources can have significant impact therapy outcome. Here, will review findings these studies, which shed light variables guide important choice or MSC diseases.

Language: Английский

---

Mesenchymal stem cells in autoimmune disease: A systematic review and meta-analysis of pre-clinical studies

Biochimie, Journal Year: 2024, Volume and Issue: 223, P. 54 - 73

Published: April 23, 2024

Language: Английский

---